FDA committee backs Novo Nordisk’s once-weekly type II diabetes drug

An FDA advisory committee has voted favorably to approve Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide Type II diabetes drug.

Shares in the insulin maker were up 2% in after-hours activity today, trading at $50.13 apiece.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA committee backs Novo Nordisk’s once-weekly type II diabetes drug appeared first on MassDevice.

from MassDevice http://ift.tt/2yy6zSX